Summary of results of trials in acute coronary syndromes comparing the addition of a GP IIb/IIIa inhibitor or placebo to heparin and conventional treatment
| Study | Drug | Intervention policy | 30 day death/MI placebo group (%) | Early PTCA + CABG |
Benefits in patients not having early intervention (30 day death/MI) | Benefits in patients waiting for intervention (death/MI) |
| PARAGON A (n=2282) | Low and high dose lamifiban (3–5 days) | Not for 48 hours unless emergency | 11.7 | 24.8% total placebo 29 % active 24% | NO placebo 11.7% active 11.3% | NO |
| PARAGON B (n=5225) | Low dose lamifiban 72 hours | Not for 24 hours unless emergency | 12.8 | 42% total no difference placebov active | NO placebo 11.3% active 10.8% | NO |
| PURSUIT (n=10 948) | Eptifibatide 72 hours | At physician's discretion | 15.7 | 24.1% total placebo 24.8% active 23.3% | NO placebo 15.6% active 14.8% | YES placebo 4.4%22 active 3.2%1-150 |
| PRISM PLUS (n=1570) | Tirofiban minimum 48 hours | Encouraged between 48 and 96 hours | 11.7 | 53.8% total no difference placebov active | NO placebo 10.1% active 7.8% | YES placebo 3.8%22 active 1.8%1-150 |
| GUSTO IV (n=7800) | Abciximab 24 or 48 hours | Not for 2–3 days unless recurrent ischaemia | 8.0 | 30% total, placebo 30% active 30% | NO placebo 8.0% active 8.6% | NO |
↵1-150 p < 0.05.